Hajime Asahina

Sapporo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Japanese clinical practice guidelines for pharmacotherapy in older adults with cancer (second edition): an overview.

Japanese clinical practice guidelines for pharmacotherapy in older adults with cancer (second edition): an overview.

Journal: International journal of clinical oncology

Published: May 02, 2026

Impact of Thyroid Transcription Factor-1 Expression on Outcomes of Platinum-Based Chemoimmunotherapy in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Impact of Thyroid Transcription Factor-1 Expression on Outcomes of Platinum-Based Chemoimmunotherapy in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.

Journal: Thoracic cancer

Published: March 31, 2026

A giant squamous cell papilloma with high fluorodeoxyglucose uptake mimicking squamous cell lung cancer: A case report.

A giant squamous cell papilloma with high fluorodeoxyglucose uptake mimicking squamous cell lung cancer: A case report.

Journal: Respiratory medicine case reports

Published: March 05, 2026

Leptomeningeal metastatic disease responding to carboplatin, pemetrexed, and amivantamab after progression to osimertinib in EGFR exon 21 L858R-Mutated non-small cell lung cancer: Two case reports.

Leptomeningeal metastatic disease responding to carboplatin, pemetrexed, and amivantamab after progression to osimertinib in EGFR exon 21 L858R-Mutated non-small cell lung cancer: Two case reports.

Journal: Respiratory medicine case reports

Published: January 21, 2026

Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.

Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 12, 2026

Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.

Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.

Journal: Cancer science

Published: January 09, 2026

Partial Response to Repotrectinib in ROS1-Rearranged Lung Squamous Cell Carcinoma: A Brief Report.

Partial Response to Repotrectinib in ROS1-Rearranged Lung Squamous Cell Carcinoma: A Brief Report.

Journal: Clinical lung cancer

Published: July 30, 2025

First Clinical Evidence of Repotrectinib Efficacy in ROS1-Rearranged NSCLC With a D2033N Resistance Mutation: Case Report.

First Clinical Evidence of Repotrectinib Efficacy in ROS1-Rearranged NSCLC With a D2033N Resistance Mutation: Case Report.

Journal: Clinical lung cancer

Published: June 13, 2025

Lung immune prognostic index as a biomarker for predicting the benefit of immune checkpoint inhibitor plus chemotherapy in older patients with non-small cell lung cancer: a secondary analysis of the NEJ057 study.

Lung immune prognostic index as a biomarker for predicting the benefit of immune checkpoint inhibitor plus chemotherapy in older patients with non-small cell lung cancer: a secondary analysis of the NEJ057 study.

Journal: International journal of clinical oncology

Published: May 03, 2025

A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).

A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).

Journal: Clinical lung cancer

Published: May 01, 2025

A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.

A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 26, 2025

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors.

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors.

Journal: Clinical lung cancer

Published: April 10, 2025

Showing 1-12 of 55

Last Updated: 09/26/2026